Avoid common mistakes on your manuscript.
Preface
A population-based cancer registry has been used for the planning and evaluation of cancer control activities based on administration and the care of individual cancer patients by those in the medical profession. The Japanese Breast Cancer Society (JBCS) registry was started in 1975. In 2004, the registry system was moved to a new system using web registration with the cooperation of the Non-Profit Organization Japan Clinical Research Support Unit and Public Health Research Foundation (Tokyo, Japan). Comprehensive individual patient data were recorded according to the Unio Internationalis Contra Cancrum (UICC) TNM classification [1] and the World Health Organization histological classification [2]. The details are described elsewhere [3]. Annual reports on this registry have since been published in Japanese and publicized through the JBCS web site to active members of the JBCS [4].
We herein report the results of a 5-year prognostic analysis of cases registered in 2005 (Figs. 1, 2, 3, 4, 5, 6, 7, 8 and 9; Supplementary Tables 1–9). The number of facilities involved in the 2005 registration was 354 and the total number of cases was 20,786. The estimated incidence of breast cancer was reported to be 50,695 cases in 2005 by the National Cancer Center [5]. Therefore, approximately 41 % of newly diagnosed breast cancer patients were included in the JBCS registry in 2005. In this prognostic study, we analyzed 9971 cases in which the survival data were available from 161 facilities. The background characteristics of the patients are summarized in Table 1. The median follow-up period was 60.0 months (range 0.1–60.0 months). Note that during the study period, not only the cutoff levels of estrogen receptor and progesterone receptor but also their corresponding test procedures were non-standardized and that trastuzumab was rarely used because it was not covered by the Japanese National Health Insurance program as an adjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. On the whole, the survival data seem to be better than expected. However, it would be prudent to avoid commenting on any specific subject because the present study is part of an annual survival report. A data set spanning multiple years would be more suitable for addressing specific subjects, such as triple-negative type or HER2 type. This is planned for the next phase studies.
Cancer control activities vary among nations and regional areas due to differences in population structures. The life expectancy for Japanese women, 87 years old in 2012, has been the longest worldwide for several years [6]. In addition, Japan is a super-aging society, with 25 % of citizens being 65 years of age or above as of October 2013, which is the highest number among all other nations [7]. We believe that the outcomes of our registry provide significant information for countries that are expected to have a similar population structure to that of Japan in the near future.
References
Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumors (UICC). 6th ed. New York: Wiley; 2002. ISBN 10: 0471222887.
Tavassoli FA, Devilee P, editors. World health organization classification of tumours: tumours of the breast and female genital organs. 4th ed. Lyon: IARC Press; 2003. ISBN 10: 9283224124.
Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer 2015; doi:10.1007/s12282-015-0599-6.
The Japanese Breast Cancer Society. https://www.med-amc.com/jcs_society/member/login/?societyCode=jbcs.
National cancer center. http://ganjoho.jp/professional/index.html.
World Health Statistics: a wealth of information on global public health. World Health Organization 2014. ISBN-13: 978-9241564717.
Cabinet Office, Government of Japan. http://www8.cao.go.jp/kourei/whitepaper/w-2014/zenbun/pdf/1s1s_1.pdf.
Acknowledgments
The authors thank all the affiliated institutes participating in the Breast Cancer Registry of the JBCS for their efforts to register the patients’ data. We extend our gratitude to staff members working at the three major institutions that contributed extensively to the present study: Sagara Hospital (Kagoshima), National Cancer Center Hospital (Tokyo), and Breastopia Namba Hospital. We also thank Dr. Muneaki Sano, a former director of Niigata Cancer Center Hospital, for his dedication to establishing the new registration system, and the staff members engaged in the registration on the Japan Clinical Research Support Unit (J-CRSU) and the Public Health Research Foundation. This work was partly supported by JSPS KAKENHI Grant Numbers 15H04796.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Anan, K., Fukui, N., Kinoshita, T. et al. Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005. Breast Cancer 23, 50–61 (2016). https://doi.org/10.1007/s12282-015-0645-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12282-015-0645-4